Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.82 PLN | -1.20% | -3.89% | -24.00% |
17/05 | Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
22/03 | Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis | CI |
Business Summary
Number of employees: 109
Sales per Business
PLN in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Small Molecule Chemicals
100.0
%
| 2 | 100.0 % | 1 | 100.0 % | -18.85% |
Sales per region
PLN in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Poland
100.0
%
| 2 | 100.0 % | 1 | 100.0 % | -18.85% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 01/12/01 | |
Director of Finance/CFO | 50 | 01/15/01 | |
Zbigniew Zaslona
CTO | Chief Tech/Sci/R&D Officer | - | - |
Samson Fung
CTO | Chief Tech/Sci/R&D Officer | - | 27/22/27 |
Marta Dudek
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
Anna Bajera
CTO | Chief Tech/Sci/R&D Officer | - | - |
Marta Borkowska
COO | Chief Operating Officer | - | 01/13/01 |
Pawel Dobrzanski
PRN | Corporate Officer/Principal | - | - |
Human Resources Officer | 53 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Tomasz Piec
BRD | Director/Board Member | - | 30/21/30 |
Chairman | - | 14/22/14 | |
Director/Board Member | - | 14/22/14 | |
Pawel Trawkowski
BRD | Director/Board Member | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 16,836,000 | 10,627,037 ( 63.12 %) | 0 | 63.12 % |
Company contact information
Sector
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-24.00% | 64.58M | |
+8.92% | 115B | |
+9.75% | 105B | |
-12.73% | 22.71B | |
+2.21% | 21.83B | |
-10.88% | 18.18B | |
-41.92% | 16.52B | |
-16.32% | 16.01B | |
+1.70% | 14.14B | |
+17.90% | 10.71B |
- Stock Market
- Equities
- MOC Stock
- Company Molecure S.A.